ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,944,993 | -0.5% | 212,995 | -5.1% | 0.04% | +9.4% |
| Q2 2023 | $20,038,442 | -22.2% | 224,519 | -6.5% | 0.03% | -25.6% |
| Q1 2023 | $25,755,849 | -15.8% | 240,215 | -4.1% | 0.04% | -17.3% |
| Q4 2022 | $30,602,112 | +15.8% | 250,570 | -2.1% | 0.05% | +10.6% |
| Q3 2022 | $26,426,000 | +7.8% | 255,928 | -3.0% | 0.05% | +14.6% |
| Q2 2022 | $24,513,000 | -22.2% | 263,709 | -1.8% | 0.04% | +2.5% |
| Q1 2022 | $31,521,000 | -15.1% | 268,595 | -2.7% | 0.04% | -2.4% |
| Q4 2021 | $37,123,000 | – | 275,953 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |